Comparative Pharmacology
Head-to-head clinical analysis: LUMIZYME versus PALYNZIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUMIZYME versus PALYNZIQ.
LUMIZYME vs PALYNZIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alglucosidase alfa is a recombinant form of human acid alpha-glucosidase (GAA), which hydrolyzes lysosomal glycogen. It provides exogenous enzyme to reduce accumulation of glycogen in lysosomes.
PALYNZIQ (pegvaliase-pqpz) is a recombinant phenylalanine ammonia lyase conjugated to polyethylene glycol. It converts phenylalanine to trans-cinnamic acid and ammonia, reducing blood phenylalanine levels in patients with phenylketonuria.
5 mg/kg administered intravenously once every 2 weeks.
2.4 mg subcutaneously once daily.
None Documented
None Documented
Terminal half-life: 1.1–3.5 hours (mean 2.2 hours) after IV infusion; due to rapid uptake into lysosomes, shorter than many enzymes.
Approximately 60–80 hours (terminal half-life); supports weekly dosing regimen.
Eliminated via reticuloendothelial system; no significant renal or biliary excretion. <5% recovered unchanged in urine.
Renal (predominantly as intact pegylated enzyme); less than 5% fecal. No active metabolites.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy